MBX Biosciences (MBX) Liabilities and Shareholders Equity (2023 - 2026)

MBX Biosciences has disclosed Liabilities and Shareholders Equity across 4 years of filings, most recently posting $452.7 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $452.7 million, up 84.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 84.4% YoY), and the FY2025 annual result was $385.1 million, up 43.42% from the prior year.
• Liabilities and Shareholders Equity came in at $452.7 million for Q1 2026 at MBX Biosciences, up from $385.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $452.7 million in Q1 2026 to a low of $84.2 million in Q4 2023.
• The 4-year median for Liabilities and Shareholders Equity is $275.5 million (2024), against an average of $293.8 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 219.0% in 2024 and jumped 41.67% in 2025, its largest moves.
• MBX Biosciences' Liabilities and Shareholders Equity stood at $84.2 million in 2023, then soared by 219.0% to $268.5 million in 2024, then jumped by 43.42% to $385.1 million in 2025, then grew by 17.54% to $452.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $452.7 million (Q1 2026), $385.1 million (Q4 2025), and $400.1 million (Q3 2025), per Business Quant data.